Preparation and Evaluation of Folate Modified PEG-PLLA Nanoparticles Loaded with Lycorine for Glioma Treatment

Jieqiong Ding,Jie Su,Binhua Luo,Liqiong Ding
DOI: https://doi.org/10.3390/molecules29051081
IF: 4.6
2024-03-01
Molecules
Abstract:Lycorine is a kind of natural active ingredient with a strong antitumor effect. In this study, folate ligand-conjugated polyethylene glycol-block-poly(l-lactide) (PEG-PLLA) nanoparticles (FA-PEG-PLLA NPs) were designed to deliver lycorine to enhance its anti-glioma activity. The successful preparation of the FA-PEG-PLLA polymer was confirmed by 1H-NMR, FT-IR, XRD, TGA, and DSC. The optimal formulation for LYC@FA-PEG-PLLA NPs was determined by response surface analysis as follows: sodium dodecyl sulfate (SDS) of 1%, carrier material of 0.03 g, organic phase volume of 3 mL, and ultrasonic power of 20%. The LYC@FA-PEG-PLLA NPs exhibited an encapsulation efficiency of 83.58% and a particle size of 49.71 nm, demonstrating good stability. Hemolysis experiments, MTT assays, and cell scratch assays revealed excellent biocompatibility of FA-PEG-PLLA and superior anti-glioma activity of LYC@FA-PEG-PLLA NPs compared to the raw drug. Additionally, cell apoptosis assays, ROS experiments, and western blot analysis demonstrated that LYC@FA-PEG-PLLA NPs contributed to cell apoptosis by inducing ROS generation and increasing the expression of NF-κB inhibitory protein IκBα. These results suggested that LYC@FA-PEG-PLLA NPs hold promise for glioma treatment.
chemistry, multidisciplinary,biochemistry & molecular biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to improve the efficacy and safety of the natural active ingredient lycorine in the treatment of glioma. Specifically, the researchers designed a folic acid - modified polyethylene glycol - polylactic acid (FA - PEG - PLLA) nanoparticle for loading lycorine to enhance its anti - glioma activity. Through this method, the researchers hope to overcome the problems of low bioavailability and poor treatment effects of lycorine due to its poor solubility and significant side effects. In addition, through folate receptor - mediated endocytosis, this nanoparticle can target tumor cells more effectively, thereby reducing the toxicity and side effects of the drug on normal cells. ### Main objectives of the paper: 1. **Improve the bioavailability of lycorine**: By encapsulating it in nanoparticles, improve its solubility and stability, thereby increasing its bioavailability in vivo. 2. **Enhance anti - glioma activity**: Through folic acid - modified nanoparticles, achieve specific targeting of glioma cells and improve the therapeutic effect of the drug. 3. **Reduce toxicity and side effects**: Through the targeted delivery of nanoparticles, reduce the impact of the drug on normal cells and reduce toxicity and side effects. ### Main research contents: - **Preparation and characterization of nanoparticles**: Through means such as proton nuclear magnetic resonance (1H - NMR), Fourier transform infrared spectroscopy (FT - IR), X - ray diffraction (XRD), thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), the successful preparation of the FA - PEG - PLLA polymer was confirmed. - **Optimization of the formula**: The optimal formula parameters, including the concentration of sodium dodecyl sulfate (SDS), the mass of the carrier material, the volume of the organic phase and the ultrasonic power, etc., were determined through response surface analysis. - **Performance evaluation**: The biocompatibility and anti - glioma activity of the nanoparticles were evaluated through methods such as hemolysis test, MTT test, cell scratch test, cell apoptosis test, reactive oxygen species (ROS) test and Western blot analysis. ### Key results: - **High encapsulation efficiency and small particle size**: The encapsulation efficiency of LYC@FA - PEG - PLLA nanoparticles is 83.58%, and the particle size is 49.71 nm, showing good stability. - **Excellent biocompatibility**: The results of the hemolysis test show that the hemolysis rate of FA - PEG - PLLA nanoparticles is less than 5%, indicating a certain degree of biosafety. - **Significant anti - glioma activity**: MTT test and cell scratch test show that the toxicity of LYC@FA - PEG - PLLA nanoparticles to C6 glioma cells is greater than that of free lycorine, and can significantly inhibit cell migration. - **Induce cell apoptosis and ROS generation**: Cell apoptosis test and ROS test show that LYC@FA - PEG - PLLA nanoparticles promote cell apoptosis by inducing ROS generation and increasing the expression of NF - κB inhibitory protein IκBα. In conclusion, this paper successfully improves the efficacy and safety of lycorine in the treatment of glioma by designing and preparing folic acid - modified polyethylene glycol - polylactic acid nanoparticles, providing new ideas for the treatment of glioma.